Risk stratification scores for major bleeding in patients with venous thromboembolism

Risk stratification scores for major bleeding in patients with venous thromboembolism

The standard treatment for venous thromboembolism (VTE) is anticoagulation. Drug selection and treatment duration will depend on the clinical presentation, the existence of provoking factors, bleeding risk, and the patient’s preferences. Anticoagulation therapy is indicated for 3-6 months in all pat...

Full description

Bibliographic Details
Main Authors:	Francisco Galeano-Valle, Lucía Ordieres-Ortega, Pablo Demelo-Rodríguez
Format:	Article
Language:	English
Published:	Permanyer 2021-01-01
Series:	Spanish Journal of Medicine
Subjects:	Venous thromboembolism. Bleeding. Mortality. Direct oral anticoagulants. Vitamin-K antagonists.
Online Access:	https://www.spanishjmed.com/frame_esp.php?id=27

Similar Items

Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management
by: Hass Bastian, et al.
Published: (2012-12-01)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
by: Ramón Lecumberri, et al.
Published: (2021-07-01)

Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018-09-01)

Platelet count and risk of major bleeding in venous thromboembolism
by: Håkon S. Johnsen, et al.
Published: (2021-05-01)

Contrasts in Glioblastoma—Venous Thromboembolism versus Bleeding Risk
by: Viktoria Muster, et al.
Published: (2021-06-01)

Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol
by: Faizan Khan, et al.
Published: (2019-10-01)

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
by: Frederikus A. Klok, et al.
Published: (2019-07-01)

Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography
by: Jaroslaw Zalewski, et al.
Published: (2020-06-01)

D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding
by: Håkon S. Johnsen, et al.
Published: (2019-01-01)

Newer oral anticoagulants in venous thromboembolism
by: Sunil Modi, et al.
Published: (2021-01-01)

A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism
by: Gabrielle Sarlon-Bartoli, et al.
Published: (2023-12-01)

Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin
by: Frank A. Lattuca, et al.
Published: (2023-03-01)

Claims‐Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism
by: Alvaro Alonso, et al.
Published: (2021-09-01)

Venous thromboembolism and major bleeding in severe and critical COVID-19 hospitalized patients
by: Veronica Abate, et al.
Published: (2023-07-01)

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
by: Shohei Migita, et al.
Published: (2023-08-01)

Oral anticoagulants: Optimizing venous thromboembolism management
by: Fahad A S. Aleidan
Published: (2019-01-01)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
by: Géraldine Poénou, et al.
Published: (2023-08-01)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
by: Yong-Jian Zhu, et al.
Published: (2021-05-01)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
by: Kochawan Boonyawat, et al.
Published: (2021-02-01)

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
by: Karsten Keller, et al.
Published: (2020-10-01)

Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies
by: Vora P, et al.
Published: (2016-08-01)

Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVID‐19
by: Scott C. Woller, et al.
Published: (2022-07-01)

Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study
by: Jennifer Howlett, et al.
Published: (2020-05-01)

Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J’xactly study
by: Shohei Migita, et al.
Published: (2023-02-01)

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
by: Yanina Balabanova, et al.
Published: (2022-02-01)

Risk Factors of Unfavorable Outcomes, Major Bleeding, and All-Cause Mortality in Patients with Venous Thromboembolism
by: Han Young Lee, et al.
Published: (2021-12-01)

Bleeding in women with venous thromboembolism during pregnancy: A systematic review of the literature
by: Camille Simard, et al.
Published: (2022-08-01)

D-dimer: a useful tool in gauging optimal duration of oral anticoagulant therapy?
by: M. Silingardi, et al.
Published: (2013-05-01)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017-08-01)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017-08-01)

Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants—A Retrospective Cohort Study
by: Irit Ayalon-Dangur, et al.
Published: (2021-12-01)

Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry
by: Di Micco P, et al.
Published: (2020-01-01)

Efficacy of the bleeding risk scoring system for optimal prophylactic anticoagulation therapy of venous thromboembolism in trauma patients: a single-center, retrospective, observational cohort study
by: Atsushi Tomizawa, et al.
Published: (2023-12-01)

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation
by: Sutee Limcharoen, et al.
Published: (2022-08-01)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
by: Alexander Cohen, et al.
Published: (2021-01-01)

A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry
by: Sabrina Kepka, et al.
Published: (2023-01-01)

Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study
by: Daniela Poli, et al.
Published: (2022-07-01)

Thromboembolism and bleeding in systemic amyloidosis: a review
by: Martin Nicol, et al.
Published: (2022-02-01)

Prevention of thromboembolic complications in patients with atrial fibrillation and obesity
by: Izabela Kolasa, et al.
Published: (2023-04-01)